Copy to clipboard 
Bioventus reported 1Q26 orthopedic sales of $118.9 million, up 7.3% compared to the first quarter of 2025.
First quarter revenue finished slightly ahead of company expectations, driven by disciplined resource allocation, increasing awareness of Bioventus’ clinical and economic value proposition and effective execution across geographies and channels.
Growth in the company’s Pain Treatments business was driven by a favorable rebated adjustment for its hyaluronic acid products.
“We had some rebate favorability and finished slightly ahead of our expectations,” said Bioventus CEO Robert Claypoole. “We called that out as it related to a one-time process change by one of our commercial payer partners, and we don’t anticipate that a similar level of variability moving forward. So we thought it’d be best to point it out. Outside of this, we delivered results consistent with our planning assumptions and expect our revenue growth to accelerate in the second half of the year as we keep executing our plan.”
The company reaffirmed its 2026 guidance of total sales between $600 million and $610 million.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $95.1 | $88.2 | $6.9 | 7.8% |
| Other | $23.8 | $22.6 | $1.2 | 5.2% |
| Total | $118.9 | $110.8 | $8.1 | 7.3% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $104.8 | $98.9 | $5.9 | 6% |
| OUS | $14.1 | $11.9 | $2.1 | 17.8% |
| Total | $118.9 | $110.8 | $8.1 | 7.3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $132.1 | |
| Cost of Sales | $41.3 | 31.3% |
| Selling and Admin | $78.3 | 59.3% |
| R&D | $2.5 | 1.9% |
| Other | $6.9 | 5.2% |
| Net Earnings | $3.1 | 2.4% |
Bioventus reported 1Q26 orthopedic sales of $118.9 million, up 7.3% compared to the first quarter of 2025.
First quarter revenue finished slightly ahead of company expectations, driven by disciplined resource allocation, increasing awareness of Bioventus' clinical and economic value proposition and effective execution across geographies...
Bioventus reported 1Q26 orthopedic sales of $118.9 million, up 7.3% compared to the first quarter of 2025.
First quarter revenue finished slightly ahead of company expectations, driven by disciplined resource allocation, increasing awareness of Bioventus’ clinical and economic value proposition and effective execution across geographies and channels.
Growth in the company’s Pain Treatments business was driven by a favorable rebated adjustment for its hyaluronic acid products.
“We had some rebate favorability and finished slightly ahead of our expectations,” said Bioventus CEO Robert Claypoole. “We called that out as it related to a one-time process change by one of our commercial payer partners, and we don’t anticipate that a similar level of variability moving forward. So we thought it’d be best to point it out. Outside of this, we delivered results consistent with our planning assumptions and expect our revenue growth to accelerate in the second half of the year as we keep executing our plan.”
The company reaffirmed its 2026 guidance of total sales between $600 million and $610 million.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| Orthobiologics | $95.1 | $88.2 | $6.9 | 7.8% |
| Other | $23.8 | $22.6 | $1.2 | 5.2% |
| Total | $118.9 | $110.8 | $8.1 | 7.3% |
Orthopedic Sales by Geography
| Region | 1Q26 | 1Q25 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $104.8 | $98.9 | $5.9 | 6% |
| OUS | $14.1 | $11.9 | $2.1 | 17.8% |
| Total | $118.9 | $110.8 | $8.1 | 7.3% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $132.1 | |
| Cost of Sales | $41.3 | 31.3% |
| Selling and Admin | $78.3 | 59.3% |
| R&D | $2.5 | 1.9% |
| Other | $6.9 | 5.2% |
| Net Earnings | $3.1 | 2.4% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
